These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

754 related items for PubMed ID: 12560826

  • 1. US policy may encourage counterfeit drugs.
    Bouchie A.
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract] [Full Text] [Related]

  • 2. Bills target biosimilar drugs.
    Wadman M.
    Nature; 2009 Mar 26; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract] [Full Text] [Related]

  • 3. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 26; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 4. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR.
    Suffolk Univ Law Rev; 2003 Dec 26; 36(3):787-819. PubMed ID: 16493844
    [No Abstract] [Full Text] [Related]

  • 5. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 6. Biotech patents-business as usual?
    Lawrence S.
    Nat Biotechnol; 2008 Dec 15; 26(12):1326. PubMed ID: 19060861
    [No Abstract] [Full Text] [Related]

  • 7. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M.
    N Engl J Med; 2006 Sep 28; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract] [Full Text] [Related]

  • 8. Indian biogenerics industry emerges.
    Jayaraman KS.
    Nat Biotechnol; 2003 Oct 28; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract] [Full Text] [Related]

  • 9. Patents: a threat to innovation?
    Manocaran M.
    Science; 2010 Jan 01; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract] [Full Text] [Related]

  • 10. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ.
    Food Drug Law J; 2007 Jan 01; 62(1):77-137. PubMed ID: 17444027
    [No Abstract] [Full Text] [Related]

  • 11. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z.
    Cornell Law Rev; 2014 Jul 01; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract] [Full Text] [Related]

  • 12. Reinventing an industry.
    Mandavilli A.
    Nature; 2007 Jan 11; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract] [Full Text] [Related]

  • 13. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA.
    Food Drug Law J; 2000 Jan 11; 55(3):321-41. PubMed ID: 11824464
    [No Abstract] [Full Text] [Related]

  • 14. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 11; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

  • 15. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV.
    Food Drug Law J; 2007 Jul 11; 62(1):249-56. PubMed ID: 17444032
    [No Abstract] [Full Text] [Related]

  • 16. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ, Graham SJ.
    Science; 2009 Oct 16; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract] [Full Text] [Related]

  • 17. Drug costs threaten patent protection.
    Cimons M.
    Nat Med; 2003 Jan 16; 9(1):9. PubMed ID: 12514706
    [No Abstract] [Full Text] [Related]

  • 18. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul 24; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract] [Full Text] [Related]

  • 19. Biotech industry struggles with generics approval.
    Knight J.
    Nature; 2004 Jun 10; 429(6992):588. PubMed ID: 15190316
    [No Abstract] [Full Text] [Related]

  • 20. US courts narrow patent exemptions.
    Fox JL.
    Nat Biotechnol; 2003 Aug 10; 21(8):834. PubMed ID: 12894182
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.